Brendan is a Director on the Life Sciences team and is responsible for the origination, evaluation and negotiation of royalty monetization transactions and investments across the capital structure in commercial-stage biopharma and medical device companies.

Brendan joined OMERS in 2013 as an equity research analyst before transferring to Life Sciences in 2017.

Brendan is a CFA® charterholder and holds a BBA from Wilfrid Laurier University.